Suggestions

Du même auteur

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Archive ouverte | Westphalen, C. B. | CCSD

International audience. Advances in precision oncology led to approval of tumour-agnostic molecularly guided treatment options (MGTOs). The minimum requirements for claiming tumour-agnostic potential remain elusive....

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

Archive ouverte | Belli, C. | CCSD

International audience. Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered...

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents

Archive ouverte | Laskin, J. | CCSD

International audience

Chargement des enrichissements...